CSF3 and Large vessel vasculitis: This may be partly due to increased awareness among clinicians, because in June 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) added large-vessel vasculitis to the list of serious adverse effects in the package insert for G-CSF preparations.